GALC Inhibitors
Common GALC Inhibitors include, but are not limited to Genistein CAS 446-72-0, PD 98059 CAS 167869-21-8, LY 294002 CAS 154447-36-6, GW 5074 CAS 220904-83-6 and SB 203580 CAS 152121-47-6.
GALC inhibitors constitute a class of compounds that influence the activity or expression of galactocerebrosidase (GALC), a pivotal enzyme involved in the metabolism of galactolipids, specifically galactosylceramide. GALC is primarily localized within lysosomes and is crucial for the degradation of galactosylceramide, preventing its accumulation within cellular compartments. The dysregulation of GALC has been implicated in the pathogenesis of Krabbe disease, a neurodegenerative disorder characterized by the accumulation of galactosylceramide, particularly in the central nervous system. GALC functions by catalyzing the hydrolysis of galactosylceramide into ceramide and galactose. This enzymatic activity is essential for maintaining the proper balance of lipids within cellular membranes and plays a critical role in the turnover of myelin sheaths in the nervous system. GALC's involvement in myelin metabolism underscores its significance in ensuring the structural integrity and functionality of the nervous system. Disturbances in GALC activity can result in the accumulation of galactosylceramide, leading to myelin degradation and subsequent neurological dysfunction.
While the specific targeting of GALC by inhibitors may not be fully elucidated, the indirect modulation of GALC activity through various cellular pathways reflects the intricate regulatory network governing lipid metabolism. Signaling cascades related to growth, differentiation, and apoptosis, as well as cellular processes involving glycosphingolipid biosynthesis, can intersect with GALC regulation. Understanding the complex interplay between GALC and these pathways provides valuable insights into points of intervention for strategies aimed at mitigating the aberrant accumulation of galactosylceramide and associated neurodegenerative conditions.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein, a tyrosine kinase inhibitor, has been implicated in modulating signaling pathways related to cell growth and differentiation. By affecting signaling cascades, it can indirectly influence cellular processes that might intersect with GALC function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of MEK1, an upstream kinase in the MAPK pathway. GALC expression can be influenced by signaling pathways, and the MAPK pathway is one such modulator. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, affecting the PI3K/Akt pathway. This pathway has connections to various cellular processes, including cell survival and growth. GALC activity might be influenced by such cellular conditions. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
GW5074 is a c-Raf inhibitor, affecting the Raf/MEK/ERK pathway. GALC expression and function can be influenced by signaling pathways, and the Raf/MEK/ERK pathway is a potential modulator. By inhibiting c-Raf, GW5074 can indirectly affect GALC through modulation of the Raf/MEK/ERK pathway, potentially altering the cellular conditions that impact GALC expression or activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK. Signaling pathways, such as p38 MAPK, can modulate GALC expression and function. By inhibiting p38 MAPK, SB203580 can indirectly impact GALC through modulation of the p38 MAPK pathway, potentially altering the cellular conditions that influence GALC expression or activity. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine is an Akt inhibitor, affecting the PI3K/Akt pathway. GALC expression and function can be influenced by signaling pathways, and the PI3K/Akt pathway is a potential modulator. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent and selective PI3K inhibitor. The PI3K/Akt pathway can influence GALC expression and function. By inhibiting PI3K, Wortmannin can indirectly impact GALC through modulation of the PI3K/Akt pathway, potentially altering the cellular conditions that influence GALC expression or activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multi-kinase inhibitor targeting Raf, VEGFR, PDGFR, and others. While not directly linked to GALC, its impact on signaling pathways related to cell survival and proliferation can potentially influence GALC indirectly. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $79.00 $321.00 $671.00 | 1 | |
Indirubin-3'-monoxime is a cyclin-dependent kinase (CDK) inhibitor. Cell cycle regulators, including CDKs, can modulate cellular conditions that affect GALC expression and function. | ||||||
TAK 715 | 303162-79-0 | sc-362799 sc-362799A | 10 mg 50 mg | $185.00 $781.00 | ||
TAK-715 is a p38 MAPK inhibitor. Signaling pathways, such as p38 MAPK, can modulate GALC expression and function. By inhibiting p38 MAPK, TAK-715 can indirectly impact GALC through modulation of the p38 MAPK pathway, potentially altering the cellular conditions that influence GALC expression or activity. | ||||||